<DOC>
	<DOC>NCT02547350</DOC>
	<brief_summary>The purpose of this study is to evaluate the efficacy of prophylactic intravesical chemotherapy (different chemotherapy drugs and dosage regimen) in the prevention of bladder recurrence after nephroureterectomy for upper tract urothelial carcinoma (UTUC).</brief_summary>
	<brief_title>Prophylactic Intravesical Chemotherapy to Prevent Bladder Tumors After Nephroureterectomy for Primary Upper Urinary Tract Urothelial Carcinomas</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Carcinoma, Transitional Cell</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<mesh_term>Pirarubicin</mesh_term>
	<criteria>1. Patients who were clinically diagnosed with UTUC 2. Treated with radical nephroureterectomy 1. Distant metastasis 2. Prior history of bladder or synchronous bladder cancer 3. Administration of neoadjuvant chemotherapy 4. Presence of severe complications.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>